Skip to main content

Third Wave Shares Climb 5 Percent on HPV Settlement

NEW YORK, Jan. 13 (GenomeWeb News) - Shares in Third Wave were up 5.26 percent, or $.17, at $3.40 in mid-afternoon trading today after the company said it settled its patent-infringement suit against Digene.

 

As GenomeWeb News reported this morning, Third Wave and Digene agreed to not sue each other over human papillomavirus products patents for one year. The settlement does not include any license or payment by either company.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.